Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Meningococcal Vaccine | BIOLOGICAL | - |
| Meningococcal (vaccine) | BIOLOGICAL | - |
Inclusion Criteria: * Healthy male or female between, and including, 15 and 19 years of age at the time of vaccination. * Subject with previously completed routine childhood vaccinations to the best of his/her knowledge or his/her parents'/guardians' knowledge. * Female subjects should be of non-ch...
Meningococcal is a monoclonal antibody being developed by GSK plc for the prevention of meningococcal infections. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being studied in healthy subjects to evaluate its safety and immunogenicity when administered as a single dose.
Meningococcal is a monoclonal antibody that targets meningococcal serogroups A, C, W-135, and Y. It is designed to provide protection against these specific serogroups of the Neisseria meningitidis bacteria, which cause meningococcal disease. The antibody is being evaluated for its ability to elicit an immune response against these serogroups.
Meningococcal is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting Phase 2 clinical trials to evaluate the safety and immunogenicity of this investigational monoclonal antibody for the prevention of meningococcal infections.
Meningococcal is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Three Phase 2 clinical trials have been completed, with a total enrollment of 300 healthy subjects. The drug is being studied for its potential to prevent meningococcal infections.
Meningococcal has completed three Phase 2 clinical trials. These include NCT00126945 and NCT00196963, which evaluated four different formulations of a meningococcal serogroups A, C, W-135, Y conjugate vaccine in healthy subjects aged 15-19 years, and NCT00196950, which evaluated the vaccine in healthy subjects aged 18-25 years. All trials were completed.
Meningococcal is a monoclonal antibody being studied for the prevention of meningococcal infections. The clinical trials for this drug evaluate formulations of a meningococcal serogroups A, C, W-135, Y conjugate vaccine. The drug is being developed to target these specific serogroups of the bacteria that cause meningococcal disease.